{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:39:58Z","timestamp":1790278798573,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod Biol Endocrinol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ovarian stimulation (OS) is one of the key factors in the success of in vitro fertilization-embryo transfer (IVF-ET), by enabling the recruitment of numerous healthy fertilizable oocytes and, thereby, multiple embryos. The Stop GnRH-agonist\/GnRH-antagonist (GnRH-ag\/GnRH-ant), which offers all the advantages of using long suppressive GnRH-ag, with GnRH-ant, is in my opinion a valuable addition to the armamentarium of OS protocols. It allows cycle programming, better follicular synchronization and offers successful outcome in a variety of challenging cases such as poor responders, Poseidon group 4 poor prognosis patients, those with elevated peak progesterone (P) serum levels, poor embryo quality or repeated IVF failures.<\/jats:p>","DOI":"10.1186\/s12958-023-01069-7","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T04:39:08Z","timestamp":1675053548000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Stop GnRH-agonist\/GnRH-antagonist protocol: a different insight on ovarian stimulation for IVF"],"prefix":"10.1186","volume":"21","author":[{"given":"Raoul","family":"Orvieto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,30]]},"reference":[{"key":"1069_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.rbmo.2012.11.001","volume":"26","author":"R Orvieto","year":"2013","unstructured":"Orvieto R, Patrizio P. GnRH agonist versus GnRH antagonist in ovarian stimulation: an ongoing debate. Reprod Biomed Online. 2013;26:4\u20138.","journal-title":"Reprod Biomed Online"},{"key":"1069_CR2","doi-asserted-by":"publisher","unstructured":"Shanbhag S, Aucott L, Bhattacharya S, Hamilton MA, McTavish AR. Interventions for \u2019poor responders\u2019 to controlled ovarian hyperstimulation (COH) in in-vitro fertilisation (IVF). Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD004379. DOI: https:\/\/doi.org\/10.1002\/14651858.CD004379.pub2","DOI":"10.1002\/14651858.CD004379.pub2"},{"issue":"3","key":"1069_CR3","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.fertnstert.2007.03.049","volume":"89","author":"R Orvieto","year":"2008","unstructured":"Orvieto R, Rabinson J, Meltcer S, Gemer O, Anteby EY, Zohav E. Does physicians\u2019 experience influence in vitro fertilization success in patients undergoing controlled ovarian hyperstimulation with GnRH antagonists? Fertil Steril. 2008;89(3):736\u20137.","journal-title":"Fertil Steril"},{"key":"1069_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.rbmo.2012.11.001","volume":"26","author":"R Orvieto","year":"2013","unstructured":"Orvieto R, Patrizio P. GnRH agonist versus GnRH antagonist in ovarian stimulation: an ongoing debate. Reprod Biomed Online. 2013;26:4\u20138. https:\/\/doi.org\/10.1016\/j.rbmo.2012.11.001.","journal-title":"Reprod Biomed Online"},{"key":"1069_CR5","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1093\/humrep\/17.9.2287","volume":"17","author":"EA Pritts","year":"2002","unstructured":"Pritts EA, Atwood AK. Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod. 2002;17:2287\u201399. https:\/\/doi.org\/10.1093\/humrep\/17.9.2287.","journal-title":"Hum Reprod"},{"issue":"12","key":"1069_CR6","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1093\/humrep\/del284","volume":"21","author":"AN Andersen","year":"2006","unstructured":"Andersen AN, Devroey P, Arce JC. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Hum Reprod. 2006;21(12):3217\u201327.","journal-title":"Hum Reprod"},{"issue":"1","key":"1069_CR7","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12958-021-00853-7","volume":"19","author":"M Kirshenbaum","year":"2021","unstructured":"Kirshenbaum M, Gil O, Haas J, Nahum R, Zilberberg E, Lebovitz O, Orvieto R. Recombinant follicular stimulating hormone plus recombinant luteinizing hormone versus human menopausal gonadotropins- does the source of LH bioactivity affect ovarian stimulation outcome? Reprod Biol Endocrinol. 2021;19(1):182.","journal-title":"Reprod Biol Endocrinol"},{"key":"1069_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13048-015-0187-6","volume":"8","author":"R Orvieto","year":"2015","unstructured":"Orvieto R. Triggering final follicular maturation\u2013hCG, GnRH-agonist or both, when and to whom? J Ovarian Res. 2015;8:60.","journal-title":"J Ovarian Res"},{"key":"1069_CR9","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1080\/09513590.2019.1576621","volume":"35","author":"J Haas","year":"2019","unstructured":"Haas J, Zilberberg E, Nahum R, Mor Sason A, Hourvitz A, Gat I, et al. Does double trigger (GnRH-agonist+hCG) improve outcome in poor responders undergoing IVF-ET cycle?\u00a0a pilot study. Gynecol Endocrinol. 2019;35:628\u201330. https:\/\/doi.org\/10.1080\/09513590.2019.1576621.","journal-title":"Gynecol Endocrinol"},{"issue":"5","key":"1069_CR10","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1159\/000517177","volume":"86","author":"R Orvieto","year":"2021","unstructured":"Orvieto R, Nahum R, Frei J, Zandman O, Frenkel Y, Haas J. GnRH-agonist ovulation trigger in patients undergoing controlled ovarian hyperstimulation for IVF with Stop GnRH-agonist combined with multidose GnRH-antagonist protocol. Gynecol Obstet Invest. 2021;86(5):427\u201331.","journal-title":"Gynecol Obstet Invest"},{"key":"1069_CR11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3389\/fendo.2020.00182","volume":"11","author":"R Orvieto","year":"2020","unstructured":"Orvieto R, Kirshenbaum M, Galiano V, Elkan-Miller E, Zilberberg E, et al. Stop GnRH-agonist combined with multiple-dose GnRH-antagonist protocol for patients with \u201cgenuine\u201d poor response undergoing controlled ovarian hyperstimulation for IVF. Front Endocrinol. 2020;11:182.","journal-title":"Front Endocrinol"},{"key":"1069_CR12","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1159\/000508875","volume":"85","author":"R Orvieto","year":"2020","unstructured":"Orvieto R, Kirshenbaum M, Galiano V, Zilberberg E, Haas J, et al. Stop GnRH agonist combined with multiple-dose GnRH-antagonist for patients with elevated peak serum progesterone levels undergoing ovarian stimulation for IVF: a proof of concept. Gynecol Obstet Invest. 2020;85:357\u201361.","journal-title":"Gynecol Obstet Invest"},{"key":"1069_CR13","first-page":"1","volume":"66","author":"R Orvieto","year":"2020","unstructured":"Orvieto R, Kirshenbaum M, Galiano V, Haas J, Nahum R. Stop GnRH-agonist combined with multiple-dose GnRH-antagonist protocol for patients with IVF failures due to poor embryo quality-a proof of concept. Clin Obstet Gynecol Reprod Med. 2020;66:1\u20133.","journal-title":"Clin Obstet Gynecol Reprod Med"},{"issue":"1\u20132","key":"1069_CR14","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000513669","volume":"86","author":"R Orvieto","year":"2021","unstructured":"Orvieto R, Nahum R, Aizer A, Haas J, Kirshenbaum MA. Novel stimulation protocol for poor-responder patients: combining the stop GnRH-ag protocol with letrozole priming and multiple-dose GnRH-ant: a proof of concept. Gynecol Obstet Invest. 2021;86(1\u20132):149\u201354.","journal-title":"Gynecol Obstet Invest"},{"key":"1069_CR15","doi-asserted-by":"crossref","unstructured":"Alviggi C, Andersen CY, Buehler K, Conforti A, De Placido G, et al (Poseidon Group (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number). A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril 2016;105:1452\u20133.","DOI":"10.1016\/j.fertnstert.2016.02.005"},{"key":"1069_CR16","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/S0015-0282(03)00544-2","volume":"80","author":"AR Baerwald","year":"2003","unstructured":"Baerwald AR, Adams GP, Pierson RA. A new model for ovarian follicular development during the human menstrual cycle. Fertil Steril. 2003;80:116\u201322.","journal-title":"Fertil Steril"},{"issue":"1","key":"1069_CR17","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.fertnstert.2005.01.117","volume":"84","author":"JA Garcia-Velasco","year":"2005","unstructured":"Garcia-Velasco JA, Moreno L, Pacheco A, Guill\u00e9n A, Duque L, Requena A, Pellicer A. The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study. Fertil Steril. 2005;84(1):82\u20137.","journal-title":"Fertil Steril"},{"key":"1069_CR18","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1210\/jcem.84.8.5929","volume":"84","author":"S Weil","year":"1998","unstructured":"Weil S, Vendola K, Zhoe J, Bondy CA. Androgen and follicle-stimulating hormone interactions in primate ovarian follicle development. J Clin Endocrinol Metab. 1998;84:2951\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1069_CR19","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1210\/endo-109-4-1303","volume":"109","author":"SG Hillier","year":"1981","unstructured":"Hillier SG, De Zwart FA. Evidence that granulosa cell aromatase induction\/activation by follicle-stimulating hormone is an androgen receptor-regulated process in-vitro. Endocrinology. 1981;109(4):1303\u20135.","journal-title":"Endocrinology"},{"issue":"3","key":"1069_CR20","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1210\/endo-119-3-1403","volume":"119","author":"CR Harlow","year":"1986","unstructured":"Harlow CR, Hillier SG, Hodges JK. Androgen modulation of follicle-stimulating hormone-induced granulosa cell steroidogenesis in the primate ovary. Endocrinology. 1986;119(3):1403\u20135.","journal-title":"Endocrinology"}],"container-title":["Reproductive Biology and Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12958-023-01069-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12958-023-01069-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12958-023-01069-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T04:45:32Z","timestamp":1675053932000},"score":1,"resource":{"primary":{"URL":"https:\/\/rbej.biomedcentral.com\/articles\/10.1186\/s12958-023-01069-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,30]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1069"],"URL":"https:\/\/doi.org\/10.1186\/s12958-023-01069-7","relation":{},"ISSN":["1477-7827"],"issn-type":[{"value":"1477-7827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,30]]},"assertion":[{"value":"21 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethics approval or consent are needed (commentary).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}